{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study demonstrates that LRRK2 interacts with 14-3-3 isoforms via phosphorylation at Ser910 and Ser935, and that disruption of this interaction by mutations like R1441C leads to accumulation of LRRK2 in cytoplasmic pools, potentially contributing to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly links the disruption of 14-3-3 binding to LRRK2's pathogenic mechanism in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses immunoprecipitation, kinase assays, and confocal microscopy to assess LRRK2's interaction with 14-3-3, its kinase activity, and cellular localization, respectively.",
          "judgment": "Yes",
          "reasoning": "These assays are standard in the field for studying protein-protein interactions, enzymatic activity, and subcellular localization, making them applicable for assessing the functional impact of LRRK2 mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type LRRK2 and uses multiple replicates, as indicated by the description of experiments being performed in duplicate or triplicate.",
          "judgment": "Yes",
          "reasoning": "The inclusion of wild-type controls and the use of multiple replicates ensure the reliability of the findings.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the R1441C mutant with other pathogenic and benign variants, assessing their impact on 14-3-3 binding and cellular localization.",
          "judgment": "Yes",
          "reasoning": "The use of variant controls, including known pathogenic mutations, strengthens the evidence that the R1441C mutation disrupts 14-3-3 binding and alters cellular localization.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a quantitative measure of pathogenicity likelihood (OddsPath) but compares the R1441C mutant's effects with those of other variants.",
          "judgment": "Yes",
          "reasoning": "While OddsPath is not calculated, the comparative analysis with other variants provides qualitative evidence of the mutation's pathogenic impact.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R1441C mutation in LRRK2 disrupts 14-3-3 binding and leads to abnormal cellular localization, supporting its classification as pathogenic with moderate functional evidence strength."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The G2019S mutation increases LRRK2's kinase activity, which is linked to Parkinson's disease pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper establishes a clear link between increased kinase activity due to G2019S and Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Kinase assays and cellular localization studies were used to assess the impact of the G2019S mutation.",
          "judgment": "Yes",
          "reasoning": "These methods are appropriate for evaluating the functional consequences of kinase domain mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes wild-type LRRK2 as a control and mentions performing experiments in duplicate or triplicate.",
          "judgment": "Yes",
          "reasoning": "The use of controls and replicates ensures the reliability of the findings.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The G2019S mutation's effects are compared with other LRRK2 variants, including those with known pathogenic effects.",
          "judgment": "Yes",
          "reasoning": "Comparative analysis with other variants provides context for the G2019S mutation's impact.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study reports a 3-fold increase in kinase activity for G2019S but does not calculate OddsPath.",
          "judgment": "Yes",
          "reasoning": "The quantitative increase in activity, though not translated into OddsPath, supports the mutation's pathogenic role.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The G2019S mutation significantly increases LRRK2's kinase activity, supporting its classification as pathogenic with moderate functional evidence strength."
    }
  ]
}